QURE ALERT: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism, Lawsuit Filed; April 13 Deadline Nears

SAN FRANCISCO, April 7, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials. This investigation follows the filing of a securities class action lawsuit seeking to represent investors who purchased or otherwise acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025 (the "Class Period"). The firm reminds investors of the April 13, 2026, Lead Plaintiff deadline in the pending securities class action.